Curriculum Pubblicazioni Congressi Libri

 

 

U.S. National Library of Medicine
National Institutes of Health

J Pineal Res. 2007 Sep;43(2):214.

Melatonin makes splenectomy unnecessary in two patients with idiopathic thrombocytopenic purpura refractory to corticosteroids.

Todisco M.

PMID: 17645700 [PubMed - indexed for MEDLINE]

 

La melatonina fa evitare la splenectomia a due pazienti con porpora trombocitopenica idiopatica refrattaria ai corticosteroidi.

 

 

 

 

U.S. National Library of Medicine
National Institutes of Health  

Am J Ther. 2003 Mar-Apr;10(2):135-6.

Severe bleeding symptoms in refractory idiopathic thrombocytopenic purpura: a case successfully treated with melatonin.

Todisco M, Casaccia P, Rossi N.

Local Health Department of National Health Service, Fermo, Italy. todmau@tin.it

Abstract

The prognosis of patients with idiopathic thrombocytopenic purpura refractory to corticosteroids and splenectomy (refractory ITP) is poor; these patients present high morbidity from disease and its treatment and have a mortality rate of approximately 16%. A patient is reported with severe bleeding symptoms related to refractory ITP successfully treated with melatonin.

PMID: 12629593 [PubMed - indexed for MEDLINE]

 

Sanguinamento severo in porpora trombocitopenica idiopatica: un caso trattato con successo con melatonina.

 

 

 

 

U.S. National Library of Medicine
National Institutes of Health

Am J Ther. 2002 Nov-Dec;9(6):524-6.

Melatonin for refractory idiopathic thrombocytopenic purpura: a report of 3 cases.

Todisco M, Rossi N.

ASL11 (Local Health Department of National Health Service), Fermo, Italy. todmau@tin.it

Abstract

In addition to its well-known influence on circadian rhythms, melatonin has been described as being able to increase the number of platelets in circulating blood. This provided the rationale to evaluate melatonin for toxicity and efficacy in three patients with idiopathic thrombocytopenic purpura (ITP) refractory to initial treatment with corticosteroids or splenectomy (refractory ITP). Patients received melatonin for 1 month. The therapy was continued for 2 additional months in patients with stable or responding disease. After 3 months, the stable or responding patients continued the therapy for 3 months and more. All patients had a partial response after 1 month. Continuing with the treatment, none of the three patients had disease progression (average follow-up time of 31 months; range: 23-46 months). Toxicity was lacking, with the only side effect being drowsiness. Our experience suggests that melatonin may be safe and effective in patients with refractory ITP.

PMID: 12424512 [PubMed - indexed for MEDLINE]

 

La Melatonina nella porpora trombocitopenica idiopatica refrattaria: report su tre casi trattati.

In aggiunta alla sua ben conosciuta influenza sui ritmi circadiani, la melatonina è stata descritta come capace di incrementare il numero delle piastrine circolanti. Ciò ci ha fornito il rationale per valutare la melatonina per tossicità ed efficacia in tre pazienti con porpora trombocitopenia idiopatica (ITP) refrattaria al trattamento iniziale con corticosteroidi o splenectomia (ITP refrattaria). I pazienti ricevevano la melatonina per 1 mese. La terapia era continuata per addizionali 2 mesi nei pazienti con malattia stabile o rispondente. Dopo tre mesi, i pazienti stabili o responsivi continuavano la terapia per tre mesi o più. Tutti i pazienti hanno avuto una risposta parziale dopo un mese. Continuando con il trattamento, nessuno dei tre pazienti ha avuto progressione di malattia (follow-up medio di 31 mesi; range da 23 a 46 mesi). La tossicità era assente, il solo effetto collaterale essendo la sonnolenza. La nostra esperienza suggerisce che la melatonina può essere sicura ed efficace nei pazienti con ITP refrattaria.